Glycopyrronium tosylate, sold under the brand name Qbrexza among others, is a medication used for the treatment of primary axillary hyperhidrosis.

[1][2][3] It was approved for medical use in the United States in June 2018,[4] and in Japan in January 2022.

[5]

This pharmacology-related article is a stub.

You can help Wikipedia by expanding it.